Our study uncovered that EGFR is also a downstream target of TEAD1 in GBM, likely through the direct binding of TEAD1 to an upstream promoter/enhancer region at EGFR. Curiously, in vitro the regulatory effect of TEAD1 on EGFR was transient, and not directly related to migration, while in vivo TEAD1-knockout xenografts showed low levels of EGFR after 3.5 months. This evidence concerns the gene EGFR and glioblastoma.